INS and type 1 diabetes mellitus: These systems have demonstrated in several RCTs [1–3] and real-world studies [4–7] to better achieve and maintain glycemic targets in people with type 1 diabetes compared to multiple dose insulin (MDI) therapy, conventional continuous subcutaneous insulin infusion (CSII) or to sensor-augmented pump (SAP) with predictive low-glucose suspend systems.